Linked Life Data

8106899

Source:http://linkedlifedata.com/resource/pubmed/id/8106899

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1994-3-22
pubmed:abstractText
The in vitro activity of OPC-17116, a new fluoroquinolone, was compared with those of ciprofloxacin, ofloxacin and cefixime. A total of 5,231 fresh clinical isolates from five geographically separate US medical centers were tested. The primary results of this study are: 1. OPC-17116 is very active against Enterobacteriaceae [MIC90s, 0.015-1 microgram/ml, except Providencia rettgeri (MIC90, > 8 micrograms/ml)], 2. among nonenteric Gram-negative bacilli (e.g. Xanthomonas maltophilia, MIC90, 2 micrograms/ml) and Gram-positive cocci (e.g. oxacillin-susceptible staphylococci, MIC90s, 0.12-0.5 microgram/ml) OPC-17116 demonstrated higher activity than ciprofloxacin or ofloxacin, 3. the quinolones were more active than cefixime against most of the species tested, especially against Gram-positive and non-enteric Gram-negative organisms. The results of this study, associated with prior documented favorable qualities, support continued investigation of OPC-17116 for clinical use.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1120-009X
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
283-8
pubmed:dateRevised
2009-8-4
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.
pubmed:affiliation
Department of Pathology, University of Iowa Hospital & Clinics, Iowa City 52242.
pubmed:publicationType
Journal Article, Comparative Study